Literature DB >> 17961568

Misoprostol for intrauterine fetal death.

R Gómez Ponce de León1, D Wing, C Fiala.   

Abstract

The frequency of intrauterine fetal death (IUFD) with retained fetus varies, but is estimated to occur in 1% of all pregnancies. The vast majority of women will spontaneously labor and deliver within three weeks of the intrauterine death. The complexity in medical management increases significantly when the cervix is unripe or unfavorable, or when the woman develops disseminated intravascular coagulation. Misoprostol regimens for the induction of labor for second and third trimester IUFDs, range from 50 to 400 microg every 3 to 12 h, and are all clinically effective. Nevertheless, the current scientific evidence supports vaginal misoprostol dosages, which are adjusted to gestational age: between 13-17 weeks, 200 microg 6-hourly; between 18-26 weeks, 100 microg 6-hourly; and more than 27 weeks, 25-50 microg 4-hourly. In women with a previous cesarean, lower doses should be used and doubling of doses should not occur. Clinical monitoring should continue after delivery or expulsion because of the risk of postpartum atony and/or placenta retention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961568     DOI: 10.1016/j.ijgo.2007.09.010

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  5 in total

1.  Route of Delivery in Women With Stillbirth: Results From the Stillbirth Collaborative Research Network.

Authors:  Annelee Boyle; Jessica P Preslar; Carol J R Hogue; Robert M Silver; Uma M Reddy; Robert L Goldenberg; Barbara J Stoll; Michael W Varner; Deborah L Conway; George R Saade; Radek Bukowski; Donald J Dudley
Journal:  Obstet Gynecol       Date:  2017-04       Impact factor: 7.661

2.  Off-label use of misoprostol in gynaecology.

Authors:  J V Turner; S Agatonovic-Kustrn; Hrg Ward
Journal:  Facts Views Vis Obgyn       Date:  2015-12-28

3.  Effectiveness and safety of sublingual misoprostol in medical treatment of the 1st trimester miscarriage: experience of off-label use in Korea.

Authors:  Jung Yeon Park; Hyo Jeong Ahn; Ba Raem Yoo; Kyu Ri Hwang; Taek Sang Lee; Hye Won Jeon; Sun Min Kim; Byoung Jae Kim
Journal:  Obstet Gynecol Sci       Date:  2018-03-02

4.  A randomized controlled trial of misoprostol and sulprostone to end pregnancy after fetal death.

Authors:  Kristin Van Mensel; Filip Claerhout; Patrick Debois; Marc J N C Keirse; Myriam Hanssens
Journal:  Obstet Gynecol Int       Date:  2009-09-06

5.  A randomized controlled trial comparing isosorbide dinitrate-oxytocin versus misoprostol-oxytocin at management of foetal intrauterine death.

Authors:  Gabriel Arteaga-Troncoso; Aide E Chacon-Calderon; Francisco J Martinez-Herrera; Sylvia G Cruz-Nuñez; Marcela Lopez-Hurtado; Aurora Belmont-Gomez; Alberto M Guzman-Grenfell; Blanca E Farfan-Labonne; Carlos J Neri-Méndez; Francisco Zea-Prado; Fernando M Guerra-Infante
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.